EUCTR2010-023837-45-DE进行中（未招募）不适用
BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria specific to each cohort:
- •1.Cohort A:
- •1a. No prior local therapy for brain metastases.
- •2a. Subjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 3 weeks prior to first dose of study treatment. (Refer to Section 5.3 Cautionary Medications).
- •3a. No prophylactic or preventive anti-epileptic therapy.;
- •2.Cohort B:
- •1b. Progression of existing lesions based on RECIST 1.1 (> 20% increase in longest diameter on baseline scan) or new lesions following local therapy for brain metastases including but not restricted to brain surgery, Whole Brain Radiotherapy (WBRT) or Stereotactic Radiosurgery (SRS e.g. gamma knife, linear-accelerated-based radiosurgery, charged particles, and CyberKnife).
- •2b. Subjects who are receiving concomitant corticosteroids must be on a stable dose for at least 2 weeks prior to first dose of study treatment. (Refer to Section 5.3 Cautionary Medications).
- •3b. Prophylactic or preventive anti-epileptic therapy is allowed (Refer to Section 5.3 Cautionary Medications).
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •4.Signed written informed consent.
- •5.Histologically confirmed metastatic melanoma (Stage IV), carrying BRAF V600E- or V600K-mutation as determined by central testing.
- •6.Up to two previous treatment regimens for extracranial metastatic melanoma including chemo-, cytokine-, immuno-, biological- and vaccine-therapy.
- •7.At least one measurable intracranial target lesion for which all of the following criteria have to be met:
- •previously untreated or progressive according to RECIST 1.1 (= 20% increase in longest diameter on baseline scan) after previous local therapy
- •immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy
- •largest diameter of = 0.5cm but = 4 cm as determined by contrast-enhanced MRI
- •for target lesions (for definition see Section 6.1.1) with diameter of > 0.5 cm but = 1 cm documented measurement by neuroradiologist is required.
- •for all lesions with diameter of = 3 cm but = 4 cm documented measurement by neuroradiologist is required.
- •8.Time interval between last day of previous anti-tumour systemic treatment and first dose of GSK2118436:
- •14 days elapsed from last treatment with surgery, SRS or gamma knife
- •28 days elapsed from last treatment with WBRT
- •= 28 days or five half-lives (whichever is longer) have elapsed from last dose of approved or investigational chemo-, cytokine-, immune-, biological-, or vaccine-therapy.
- •8.Age =18 years of age.
- •9.Able to swallow and retain oral medication
- •10.Must be able to understand and comply with protocol requirements and instructions.
- •11.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 [Oken, 1982].
- •12.Must have adequate organ function as defined by the following screening values (Retesting of borderline screening organ function and treatment with blood transfusions, growth factors etc. will be allowed):
- •Absolute neutrophil count (ANC) =1.5x109/L
- •Haemoglobin =9 g/dL
- •Platelets =100 x109/L
- •Serum bilirubin =1.5 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5xULN
- •Serum Creatinine =1.5 mg/dL (If serum creatinine is >1.5 mg/dL, calculate creatinine clearance using standard Cockcroft and
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •1.Neurological symptoms related to brain metastasis.
- •2.Previous treatment with a BRAF or MEK inhibitor.
- •3.Current or expected use of a prohibited medication (Refer to Section 5.2 Prohibited Medications including enzyme inducing antiepileptic drugs [EIAEDs]) during treatment with GSK2118436.
- •4.Presence of leptomeningeal disease or primary dural metastases.
- •5.Known allergies against contrast agents required for magnetic resonance imaging (MRI) of intracranial lesions.
- •6.Current use of therapeutic warfarin.
- •NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permitted.
- •7.Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous anti-cancer therapy, except alopecia.
- •8.Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor to determine eligibility.
- •9.A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. Subjects with laboratory evidence of HBV clearance may be enrolled.
- •10.Acute infection requiring intravenous antibiotics.
- •11.A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- •12.History of another malignancy.
- •Exception: (a) a history of completely resected non-melanoma skin cancer, (b) successfully treated in situ carcinoma, (c) CLL in stable remission, or (d) indolent prostate cancer requiring no or only anti-hormonal therapy with histologically confirmed tumour lesions that can be clearly differentiated from melanoma target and non-target lesions are eligible.
- •13.The following cardiac abnormalities:
- •Corrected QT (QTc) interval =480 msecs
- •History of acute coronary syndromes (including unstable angina) within the past 24 weeks.
- •Coronary angioplasty or stenting within the past 24 weeks.
- •Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
- •Abnormal cardiac valve morphology (= Grade 2) documented by echocardiogram (subjects with Grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
- •History of known cardiac arrhythmias (except sinus arrhythmia) within the past 24 weeks.
- •Known cardiac metastases.
- •14.Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, or unwillingness or inability to follow the procedures required in the protocol.
- •15.Pregnant, lactating or breastfeeding females.
研究者
相似试验
进行中（未招募）
1 期
Open-Labeled Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the BrainMedDRA version: 19.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2013-003452-21-DEovartis Pharma Services AG120
进行中（未招募）
1 期
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the BrainEUCTR2013-003452-21-ITGlaxoSmithKline Research & Development Ltd125
进行中（未招募）
1 期
Open-Labeled Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.EUCTR2013-003452-21-ESGlaxoSmithKline, S.A.120
进行中（未招募）
1 期
The purpose of this study is to learn about the initial effects and safety of MOR00208, given together with idelalisib or venetoclax for treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). MOR00208 is an investigational drug - one that is not approved for use in this country. Idelalisib and venetoclax are approved in many countries including this country for treatment of CLL and in the United States for treatment of CLL/ SLL (idelalisib) and CLL (venetoclax).Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-002915-14-DEMorphoSys AG24
进行中（未招募）
1 期
The purpose of this study is to learn about the initial effects and safety of MOR00208, given together with idelalisib or venetoclax for treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). MOR00208 is an investigational drug - one that is not approved for use in this country. Idelalisib and venetoclax are approved in many countries including this countryfor treatment of CLL and in the United States for treatment of CLL/ SLL (idelalisib) and CLL (venetoclax).Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-002915-14-ATMorphoSys AG24